Center for Childhood Cancer Research Cell Therapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Address correspondence to: David M. Barrett, CCCR Cell Therapy Program, Children’s Hospital of Philadelphia, Oncology/BMT CTRB 3032, 3501 Civic Center Boulevard, Philadelphia, Pennsylvania 19104-4318, USA. Phone: 267.426.9740; Email: email@example.com.
First published April 15, 2019 - More info
Chimeric antigen receptor (CAR) T cells are an effective therapy for relapsed or refractory pediatric B cell leukemia. Analysis of the starting material, the T cells collected from the patient prior to CAR manufacture, reveals possible biomarkers of cells destined to perform poorly in patients. Long-term follow-up shows that long periods of B cell aplasia, a marker of in vivo CAR activity, are associated with longer remission but also a higher chance of antigen-negative relapse. The role of transplantation as consolidative therapy is unclear in this nonrandomized data, but clearly warrants further study.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.